Yifan Pharmaceutical Future Growth
Future criteria checks 4/6
Yifan Pharmaceutical is forecast to grow earnings and revenue by 68.6% and 17.4% per annum respectively. EPS is expected to grow by 68.5% per annum. Return on equity is forecast to be 8.4% in 3 years.
Key information
68.6%
Earnings growth rate
68.5%
EPS growth rate
Pharmaceuticals earnings growth | 19.5% |
Revenue growth rate | 17.4% |
Future return on equity | 8.4% |
Analyst coverage | Low |
Last updated | 20 Aug 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively
Jun 04Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story
May 08A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price
Mar 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7,377 | 930 | N/A | 699 | 3 |
12/31/2025 | 6,413 | 774 | N/A | 952 | 3 |
12/31/2024 | 5,367 | 551 | N/A | -92 | 3 |
6/30/2024 | 4,756 | -407 | -166 | 339 | N/A |
3/31/2024 | 4,456 | -470 | 11 | 527 | N/A |
12/31/2023 | 4,068 | -551 | -156 | 349 | N/A |
9/30/2023 | 4,038 | 135 | -128 | 456 | N/A |
6/30/2023 | 4,011 | 139 | -126 | 442 | N/A |
3/31/2023 | 3,869 | 135 | -5 | 520 | N/A |
1/1/2023 | 3,837 | 191 | -70 | 472 | N/A |
9/30/2022 | 3,740 | 191 | -146 | 247 | N/A |
6/30/2022 | 3,801 | 226 | -228 | 259 | N/A |
3/31/2022 | 4,115 | 267 | -419 | 106 | N/A |
1/1/2022 | 4,409 | 278 | -271 | 301 | N/A |
9/30/2021 | 4,656 | 348 | -389 | 348 | N/A |
6/30/2021 | 4,967 | 463 | -178 | 587 | N/A |
3/31/2021 | 5,276 | 777 | 313 | 1,051 | N/A |
12/31/2020 | 5,400 | 968 | 393 | 1,109 | N/A |
9/30/2020 | 5,533 | 1,073 | 756 | 1,644 | N/A |
6/30/2020 | 5,480 | 1,136 | 754 | 1,573 | N/A |
3/31/2020 | 5,376 | 1,080 | 267 | 1,190 | N/A |
12/31/2019 | 5,187 | 903 | 71 | 937 | N/A |
9/30/2019 | 4,994 | 769 | -181 | 641 | N/A |
6/30/2019 | 4,824 | 683 | -189 | 592 | N/A |
3/31/2019 | 4,515 | 559 | 43 | 732 | N/A |
12/31/2018 | 4,632 | 737 | 442 | 1,171 | N/A |
9/30/2018 | 4,742 | 1,140 | 737 | 1,394 | N/A |
6/30/2018 | 4,842 | 1,364 | 821 | 1,445 | N/A |
3/31/2018 | 4,760 | 1,431 | N/A | 1,425 | N/A |
12/31/2017 | 4,373 | 1,305 | N/A | 1,133 | N/A |
9/30/2017 | 3,900 | 1,045 | N/A | 1,033 | N/A |
6/30/2017 | 3,630 | 821 | N/A | 1,085 | N/A |
3/31/2017 | 3,548 | 768 | N/A | 954 | N/A |
12/31/2016 | 3,505 | 705 | N/A | 856 | N/A |
9/30/2016 | 3,282 | 604 | N/A | 586 | N/A |
6/30/2016 | 2,948 | 554 | N/A | 468 | N/A |
3/31/2016 | 2,664 | 413 | N/A | 341 | N/A |
12/31/2015 | 2,435 | 361 | N/A | 402 | N/A |
9/30/2015 | 2,446 | 420 | N/A | 343 | N/A |
6/30/2015 | 2,237 | 327 | N/A | 147 | N/A |
3/31/2015 | 1,930 | 280 | N/A | 142 | N/A |
12/31/2014 | 1,685 | 238 | N/A | 140 | N/A |
9/30/2014 | 1,414 | 148 | N/A | 102 | N/A |
6/30/2014 | 1,327 | 146 | N/A | 95 | N/A |
3/31/2014 | 1,331 | 155 | N/A | 86 | N/A |
12/31/2013 | 1,158 | 118 | N/A | 34 | N/A |
9/30/2013 | 968 | 70 | N/A | 42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002019 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 002019 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 002019 is expected to become profitable in the next 3 years.
Revenue vs Market: 002019's revenue (17.4% per year) is forecast to grow faster than the CN market (13.3% per year).
High Growth Revenue: 002019's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002019's Return on Equity is forecast to be low in 3 years time (8.4%).